News from blueprint medicines corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 04, 2023, 16:01 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective December 1, 2023, the Compensation Committee of Blueprint Medicines'...

Nov 28, 2023, 08:00 ET Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP...

Nov 10, 2023, 08:00 ET Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Nov 03, 2023, 16:01 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective November 1, 2023, the Compensation Committee of Blueprint Medicines'...

Oct 26, 2023, 07:00 ET Blueprint Medicines Reports Third Quarter 2023 Results

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the third quarter ended September...

Oct 12, 2023, 08:00 ET Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday,...

Oct 05, 2023, 16:01 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint Medicines'...

Sep 05, 2023, 16:01 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint Medicines' ...

Aug 04, 2023, 16:16 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint Medicines'...

Aug 02, 2023, 07:00 ET Blueprint Medicines Reports Second Quarter 2023 Results

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30,...

Jul 19, 2023, 08:00 ET Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday,...

Jul 05, 2023, 16:30 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint Medicines'...

Jun 05, 2023, 17:00 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective June 1, 2023, the Compensation Committee of Blueprint Medicines'...

Jun 03, 2023, 09:00 ET Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 ...

May 23, 2023, 10:00 ET NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group, has...

May 22, 2023, 16:04 ET FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT® (avapritinib)...

May 04, 2023, 17:01 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines' Board...

May 04, 2023, 07:00 ET Blueprint Medicines Reports First Quarter 2023 Results

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31,...

Apr 26, 2023, 10:00 ET Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision...

Apr 20, 2023, 16:01 ET Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May...

Apr 11, 2023, 08:00 ET Blueprint Medicines to Present at Upcoming Investor Conferences

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its participation in the following upcoming investor conferences: 22nd Annual Needham...

Apr 05, 2023, 16:01 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Mar 28, 2023, 16:05 ET Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on ...

Mar 07, 2023, 16:01 ET Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Feb 26, 2023, 15:00 ET Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

-- AYVAKIT achieved a statistically significant and clinically meaningful improvement in total symptom score that deepened over time, with...